Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Guldane Cengiz Seval, Isinsu Kuzu, Seher Yuksel, Gulsah Kaygusuz, Klara Dalva, MD, Muhit Ozcan, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3197.

https://doi.org/10.1182/blood-2019-127541

Published: 2019

Journal Articles

Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Osman Ilhan, MD, Pinar Ataca, MD, Erden Atilla, MD, Selami Kocak Toprak, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD, Sinem Civriz Bozdag, MD, Pervin Topcuoglu, MD, Onder Arslan, MD, Muhit Ozcan, MD, Meral Beksac, MD, Taner Demirer, MD, Hamdi Akan, MD, Nahide Konuk, MD, Gunhan Gurman, MD

Blood (2014) 124 (21): 5555.

https://doi.org/10.1182/blood.V124.21.5555.5555

Published: 2014

Journal Articles

Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside

Pinar Ataca, MD, Selami Kocak Toprak, MD, Erden Atilla, MD, Pervin Topcuoglu, MD, Meltem Kurt Yuksel, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD, Onder Arslan, MD, Muhit Ozcan, MD, Osman Ilhan, MD, Nahide Konuk, MD

Blood (2014) 124 (21): 5462.

https://doi.org/10.1182/blood.V124.21.5462.5462

Published: 2014

Journal Articles

Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More.

Selami Kocak Toprak, MD, Gulsah Kaygusuz, MD, Nazmiye Kursun, Duygu Ozu, Merih Kizil Cakar, MD, Isinsu Kuzu, MD, Meral Beksac, MD

Blood (2010) 116 (21): 1345.

https://doi.org/10.1182/blood.V116.21.1345.1345

Published: 2010

Journal Articles

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Selami Kocak Toprak, MD, Merih Kizil, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD

Blood (2005) 106 (11): 5117.

https://doi.org/10.1182/blood.V106.11.5117.5117

Published: 2005

NARROW

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside

Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More.

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside

Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More.

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only